Genomic Translation for Amyotrophic Lateral Sclerosis Care
The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.
Disease:Amyotrophic Lateral Sclerosis (ALS), Familial ALS, Sporadic ALS, Primary Lateral Sclerosis (PLS)
Study Type:Observational Study
Study Category:Neals Affiliated, Diseases, Study Type, Study Status, Phase, Gender
Study Chair(s)/Principal Investigator(s):
Matthew Harms, MD, Columbia University
Clinicaltrials.gov ID (11 digit #):NCT02795897
Coordinating Center Contact InformationColumbia University
Full Study Summary:
In all patients, ALS/MND is caused by the progressive death of motor neurons. However, every patient is affected differently. Some develop symptoms in their 80's while others get sick in adolescence. Swallowing/speech are affected first in some patients, but most have weakness in their hands or feet at onset. Some individuals show very rapid progression, even as others live for decades. Finally, some patients have loss of mainly motor neurons in the brain (as in primary lateral sclerosis), while others lose mainly lower motor neurons in the spinal cord and brain stem (as in progressive muscular atrophy). Research has uncovered a few genetic factors that contribute to the variability of ALS/MND. For example, mutations in the superoxide dismutase 1 (SOD1) gene makes onset in the legs more likely and decreases the chance of developing dementia. Conversely, having a mutated C9ORF72 gene makes dementia much more likely. Uncovering additional factors causing ALS variability is an important research priority and is likely to provide clues about how to better diagnose and treat the disease.
This study is called "Genomic Translation for ALS Care" (GTAC). The investigators will analyze the genome and gene expression patterns of people with ALS/MND and carry out research on that data, finding insights that the investigators hope will translate into better care for ALS/MND patients.
Study Sponsor:Columbia University
Estimated Study Start Date:05/31/2016
Estimated Study Completion Date:05/31/2019
Posting Last Modified Date:06/27/2017
Date Study Added to alsconsortium.org:06/21/2016
Time since Symptom Onset:
Time since Diagnosis:
Can participants use Riluzole?
-Men or women of any race or ethnicity aged 18 or older
-Diagnosis of familial or sporadic ALS (definite, probable, or possible according to El Escorial Criteria, Appendix 1), or those with primary lateral sclerosis or progressive bulbar/muscular atrophy forms of motor neuron disease. All-comers with ALS/MND should be enrolled without regard to familial vs sporadic or gene mutation status (i.e. participants with known gene mutations should still be enrolled), or phenotype.
-Capable of providing informed consent and following study procedures (in the case that a subject lacks the ability to provide informed consent, informed consent will be sought from the subject's surrogate representative).
-Willing to return to clinic site (or another participating center) for follow-up care.
-Invasive ventilation (i.e. tracheostomy) in place.
-Non-invasive ventilation dependent (defined as >22 hours per day)
-Known Human Immunodeficiency Virus (HIV) , chronic Hepatitis B, or Hepatitis C (because cells will be frozen down for future cell line generation).
Site Contact Information
Cedar Sinai Medical Center
Los Angeles, California 90048
Univeristy of Michigan
Ann Arbor, Michigan 48109
University of Minnesota
Minneapolis, Minnesota 55455
St. Louis, Missouri 63110
New York, New York 10032
Duke ALS Clinic
932 Morreene Road
Durham, North Carolina 27705
Penn State College of Medicine
Hershey, Pennsylvania 17033
Houston Methodist Neurological Institute
Houston, Texas 77030
University of Utah
Salt Lake City, Utah 84112
University of Washington
Seattle, Washington 98195
The University of Edinburgh